Article
Future directions for precision oncology in prostate cancer
3 Jun 2022
Abstract excerpt
Clinical genomic testing is becoming routine in prostate cancer, as biomarker-driven therapies such as poly-ADP ribose polymerase (PARP) inhibitors and anti-PD1 immunotherapy are now approved for select men with castration-resistant prostate cancer harboring alterations in DNA repair genes. Challenges for precision medicine in prostate cancer include an overall low prevalence of actionable genomic alterations and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
